Showing 2741-2750 of 5909 results for "".
- ReVision Therapeutics Announces License With Cornell to Develop Treatment for Stargardt Diseasehttps://modernod.com/news/revision-therapeutics-announces-license-with-cornell-to-develop-treatment-for-stargardt-disease/2478230/ReVision Therapeutics announced that it has signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic d
- Genentech Initiates Phase 3 Trial for Port Delivery System with Ranibizumab in Diabetic Retinopathyhttps://modernod.com/news/late-stage-trial-starts-for-port-delivery-system-with-ranibizumab-in-diabetic-retinopathy/2478224/Genentech has initiated a new phase 3 clinical trial investigating Port Delivery System with ranibizumab (PDS) for people with diabetic retinopathy (DR). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of r
- Seva Foundation Partners With IrisVision to Democratize Vision Care Through Innovationhttps://modernod.com/news/seva-foundation-partners-with-irisvision-to-democratize-vision-care-through-innovation/2478208/IrisVision announced it has partnered with the Seva Foundation to develop new technology that aims to democratize vision healthcare around the world. In the first phase of this unique public-private partnership, Seva, a global non-profit organization that provides eye
- ForwardVue Pharma Secures Funding to Advance Preclinical Development Programshttps://modernod.com/news/forwardvue-pharma-secures-funding-to-advance-preclinical-development-programs/2478206/ForwardVue Pharma has secured initial seed round funding in order to advance preclinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. Based on this progress, ForwardVue has announced a ne
- Regenxbio Announces FDA Clearance of IND for Phase 2 Trial of RGX-314 for the Treatment of DR Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-fda-clearance-of-ind-for-phase-2-trial-of-rgx-314-for-the-treatment-of-dr-using-suprachoroidal-delivery/2478202/Regenxbio announced the clearance of the investigational new drug (IND) application by the FDA to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and Regenxbio plans to begin dosing patients in a phase 2 trial, ALTITUDE, in the second
- Gyroscope Therapeutics Announces FDA Clearance of Orbit Subretinal Delivery Systemhttps://modernod.com/news/gyroscope-therapeutics-announces-fda-clearance-for-orbit-subretinal-delivery-system/2478198/Gyroscope Therapeutics announced that the FDA has granted 510(k) clearance for the Orbit Subretinal Delivery System (Orbit SDS). The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye. The microinjection procedure is designed to avoid damaging the structure
- Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targetshttps://modernod.com/news/pharma-company-exercises-rights-for-exclusive-use-of-everads-drug-delivery-technology-in-specific-retinal-targets/2478193/Everads Therapy has granted a pharmaceutical company a time-limited exclusivity for utilizing Everads’ suprachoroidal delivery technology for the development of specific ocular targets. In exchange for exclusivity of these specific ocular targets, Everads will receive a milestone payment. E
- LensGen Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directorshttps://modernod.com/news/lensgen-closes-10-million-financing-and-welcomes-james-v-mazzo-to-its-board-of-directors/2478182/LensGen announced the initial closing of a $10 million of the $20 million Bridge Financing and announcd the election of James Mazzo to its Board of Directors.
- Safer and More Effective Glaucoma Surgical Options Will Drive Surgery Device Treatment Penetration Over Next Five Yearshttps://modernod.com/news/safer-and-more-effective-glaucoma-surgical-options-will-drive-surgery-device-treatment-penetration-over-next-five-years/2478181/Expanding use of surgical devices in patients with all stages of glaucoma will increase the role of surgery in the glaucoma treatment paradigm over the next 5 years, according to a Market Scope report. There are four FDA-approved minimally invasive glaucoma surgery (MIGS) stents in the US:
- Patient Safety Advocate Group Calls for Congressional Action to Prevent Implementation of Contact Lens Rulehttps://modernod.com/news/patient-safety-advocate-group-calls-for-congressional-action-to-prevent-implementation-of-contact-lens-rule/2478178/The Health Care Alliance for Patient Safety (APS) released the following statement regarding the Federal Trade Commission’s (FTC) publication of the Contact Lens Rule in the Federal Register. The rule